Vascular endothelial growth factor in node-positive breast cancer patients treated with adjuvant tamoxifen

D. Coradini, E. Biganzoli, C. Pellizzaro, S. Veneroni, S. Oriana, F. Ambrogi, R. Erdas, P. Boracchi, M. G. Daidone, E. Marubini

Research output: Contribution to journalArticle

Abstract

In 212 postmenopausal women with node-positive oestrogen receptor-positive (ERLBA) breast cancer subjected to radical surgery and adjuvant tamoxifen, the risk of 6-year relapse increased with increasing values of intratumoral vascular endothelial growth factor (VEGF) in patients whose tumours had a low/intermediate ERLBA content compared to patients with high-ERLBA tumours. These findings indicate that tumour progression, activated or sustained by high VEGF levels, may be counteracted in high-ERLBA cancers by tamoxifen, which in contrast fails to contrast the metastatic potential in low-ERLBA tumours.

Original languageEnglish
Pages (from-to)268-270
Number of pages3
JournalBritish Journal of Cancer
Volume89
Issue number2
DOIs
Publication statusPublished - Jul 21 2003

Keywords

  • Node-positive breast cancer
  • Steroid receptors
  • Tamoxifen
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Vascular endothelial growth factor in node-positive breast cancer patients treated with adjuvant tamoxifen'. Together they form a unique fingerprint.

Cite this